MARKET

CTKB

CTKB

Cytek BioSciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.11
-0.29
-1.19%
After Hours: 24.11 0 0.00% 16:00 09/24 EDT
OPEN
24.20
PREV CLOSE
24.40
HIGH
24.33
LOW
23.08
VOLUME
140.39K
TURNOVER
--
52 WEEK HIGH
28.70
52 WEEK LOW
17.40
MARKET CAP
3.22B
P/E (TTM)
980.08
1D
5D
1M
3M
1Y
5Y
Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. Cytek’s management...
GlobeNewswire · 09/02 20:05
Cytek Biosciences Q2 Net Income Falls, Revenue Rises
MT Newswires · 09/02 17:37
BRIEF-Cytek Bio Says Co, Unit Entered Into A Supply Agreement With Coherent
reuters.com · 08/30 22:11
Cytek Biosciences Says On Aug. 25 Entered Into Supply Agreement With Coherent; Coherent To Sell, Supply To Co Laser Products
On August 25, 2021, Cytek Biosciences, Inc. and Cytek (Wuxi) Biosciences Co., Ltd, a China subsidiary of Cytek Biosciences, Inc. (together, “Cytek”) entered into a Supply Agreement (the
Benzinga · 08/30 20:14
Cowen & Co. Initiates Coverage On Cytek Biosciences with Outperform Rating
Cowen & Co. analyst Max Masucci initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Outperform rating.
Benzinga · 08/17 15:56
Morgan Stanley Initiates Coverage On Cytek Biosciences with Equal-Weight Rating, Announces Price Target of $26
Morgan Stanley analyst Tejas Savant initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight rating and announces Price Target of $26.
Benzinga · 08/17 12:10
Piper Sandler Initiates Coverage On Cytek Biosciences with Overweight Rating, Announces Price Target of $28
Piper Sandler analyst Steven Marotta initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $28.
Benzinga · 08/17 09:29
--Morgan Stanley Starts Cytek Biosciences at Equal-Weight With $26 Price Target
MT Newswires · 08/17 08:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTKB. Analyze the recent business situations of Cytek BioSciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTKB stock price target is 27.00 with a high estimate of 28.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 133.69M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.19%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chief Executive Officer/Co-Founder/Director
Wenbin Jiang
Co-Founder/Chief Technology Officer/Director
Ming Yan
Chief Financial Officer/Primary Contact
Patrik Jeanmonod
Vice President/Director of Sales
Steve Ziganti
General Manager
Ken Riley
No Data
About CTKB
Cytek Biosciences, Inc is a cell analysis solutions company. The Company offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). Its FSP technology optimizes through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide a suite of solutions for its customers. Its FSP platform addresses the limitations of other technologies by providing a density of information for performance. Its patented FSP technology is designed to optimize through its optical and electronic designs that utilizes a method of light detection and distribution to a selected number of detectors of a particular type.

Webull offers kinds of Cytek Biosciences Inc stock information, including NASDAQ:CTKB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTKB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTKB stock methods without spending real money on the virtual paper trading platform.